Modeling HCV kinetics under therapy using PK and PD information

Bibliography

• Barria MI, Vera-Otarola J, Leon U, et al. Influence of extrahepatic viral infection on the natural history of hepatitis C. Ann Hepatol 2008;7:136-43
   PubMed Web of Science ®Google Scholar
• Lerat H, Berby F, Trabaud MA, et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 1996;97:845-51
   PubMed Web of Science ®Google Scholar
• Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004;40:341-52
   PubMed Web of Science ®Google Scholar
• Old and new HCV genotypes in the database. Theoretical Biology and Biophysics. Los Alamos, NM: 2003. Available from: http://hcv.lanl.gov/content/sequence/HCV/classification/genotable.html [Last accessed 30 January 2009]
   Google Scholar
• Hepatitis C. World Health Organization. Switzerland: 2000. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/ [Last accessed 30 January 2009]
   Google Scholar
• Distribution of HCV sequences: World. Theoretical Biology and Biophysics. Los Alamos, NM: HCV sequence database, 2003. Available from: http://hcv.lanl.gov/components/sequence/HCV/new_geography/geography.comp?region=world&form=show&organism=HCV [Last accessed 30 January 2009]
   Google Scholar
• Waiting list candidates. The Organ Procurement and Transplantation Network. Richmond, VA: 2009. Available from: http://www.optn.org/ [Last accessed 30 January 2009]
   Google Scholar
• Package Insert PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection. Kenilworth, NJ: Schering Corporation, 2001
   Google Scholar
• Package Insert PEGASYS® (peginterferon alfa-2a). Nutley, NJ: Hoffmann-La Roche Inc., 2002
   Google Scholar
• Roferon-A (Interferon alfa-2a, recombinant). Nutley, NJ: Hoffmann-La Roche Inc., 2008
   Google Scholar
• INTRON® A Interferon alfa-2b, recombinant For Injection. Kenilworth, NJ: Schering Corporation, 2008
   Google Scholar
• Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 2004;24(Suppl 2):33-8
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51
   PubMed Web of Science ®Google Scholar
• Foster GR. Better by Design. A guide to PEGylation, pharmacokinetics and pegylated interferons. Basel, Switzerland: Roche, 2003
   Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C intervention therapy group. Clin Pharmacol Ther 2000;68:556-67
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008;48:407-17
   PubMed Web of Science ®Google Scholar
• Albuferon® (albinterferon alfa-2b). Human Genome Sciences. Rockville, MD: 2008. Available from: http://www.hgsi.com/albuferona.html [Last accessed 30 January 2009]
   Google Scholar
• Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-8
   PubMed Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-9
   PubMed Web of Science ®Google Scholar
• Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008;48:398-406
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Nelson DR, Marcellin P. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care? Antivir Ther 2008;13:747-60
   PubMed Web of Science ®Google Scholar
• Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6
   PubMed Web of Science ®Google Scholar
• Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6
   PubMed Web of Science ®Google Scholar
• Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002;2:28-36
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7
   PubMed Web of Science ®Google Scholar
• Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006;63:832-42
   PubMed Web of Science ®Google Scholar
• Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003;37:1343-50
   PubMed Web of Science ®Google Scholar
• Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97
   PubMed Web of Science ®Google Scholar
• Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52
   PubMed Web of Science ®Google Scholar
• Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8
   PubMed Web of Science ®Google Scholar
• Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60
   PubMed Web of Science ®Google Scholar
• Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-51
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103
   PubMed Web of Science ®Google Scholar
• Karino Y, Toyota J, Sugawara M, et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003;18:404-10
   PubMed Web of Science ®Google Scholar
• Layden JE, Layden TJ, Reddy KR, et al. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002;9:340-5
   PubMed Web of Science ®Google Scholar
• Shudo E, Ribeiro RM, Talal AH, et al. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 2008;13:919-26
   PubMed Web of Science ®Google Scholar
• Talal AH, Ribeiro RM, Powers KA, et al. Pharmacodynamics of PEG-IFN a differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006;43:943-53
   PubMed Web of Science ®Google Scholar
• Sherman KE, Shire NJ, Rouster SD, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005;128:313-27
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003;188:1498-507
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1438-47
   PubMed Web of Science ®Google Scholar
• Shudo E, Ribeiro RM, Perelson AS. Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat 2008;15:357-62
   PubMed Web of Science ®Google Scholar
• Shudo E, Ribeiro RM, Perelson AS. Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b. J Viral Hepat 2008;15:379-82
   PubMed Web of Science ®Google Scholar
• Powers KA, Dixit NM, Ribeiro RM, et al. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003;23(Suppl 1):13-8
   PubMed Web of Science ®Google Scholar
• Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002;35:930-6
   PubMed Web of Science ®Google Scholar
• Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003;10:271-6
   PubMed Web of Science ®Google Scholar
• Lake-Bakaar G, Ruffini L, Kuzmic P. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci 2003;48:126-39
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Weiner D. Third edition. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. Stockholm, Sweden: Apotekarsocieteten, 2000
   Google Scholar
• Welling PG. Pharmacokinetics : processes and mathematics. Washington, DC: American Chemical Society, 1986
   Google Scholar
• Wagner JG. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 1968;20:173-201
   PubMed Web of Science ®Google Scholar
• Dixit NM, Perelson AS. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol 2004;226:95-109
   PubMed Web of Science ®Google Scholar
• Bekkering FC, Neumann AU, Brouwer JT, et al. Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 2001;1:14
   PubMedGoogle Scholar
• Dahari H, Lo A, Ribeiro RM, et al. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007;247:371-81
   PubMed Web of Science ®Google Scholar
• Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007;46:16-21
   PubMed Web of Science ®Google Scholar
• Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351-8
   PubMed Web of Science ®Google Scholar
• Dahari H, Feliu A, Garcia-Retortillo M, et al. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005;42:491-8
   PubMed Web of Science ®Google Scholar
• Seber GAF, Wild CJ. Nonlinear Regression. New York: Wiley, 1989
   Google Scholar
• Dahari H, Shudo E, Ribeiro RM, et al. Mathematical modeling of HCV infection and treatment. Methods Mol Biol 2009;510:439-53
   PubMedGoogle Scholar
• Dahari H, Shudo E, Ribeiro RM, et al. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 2009;49:32-8
   PubMed Web of Science ®Google Scholar
• Callaway DS, Perelson AS. HIV-1 infection and low steady state viral loads. Bull Math Biol 2002;64:29-64
   PubMed Web of Science ®Google Scholar
• Telaprevir (VX-950). Vertex Pharmaceuticals. Cambridge, MA: 2008. Available from: http://www.vpharm.com/current-projects/drug-candidates/telaprevir-VX-950.html [Last accessed 25 November 2008]
   Google Scholar
• Investor update. Hoffmann-La Roche Ltd. Nutley, NJ: 2008. Available from : http://www.roche.com//investors/ir_update/inv-update-2008-04-28b.htm [Last accessed 25 November 2008]
   Google Scholar
• Liang Y, Ishida H, Lenz O, et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 2008;135:1710-18e2
   PubMed Web of Science ®Google Scholar
• Farley S. A double whammy for hep C. Nat Rev Drug iscov 2003;2:419
   Web of Science ®Google Scholar
• Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001;75:8516-23
   PubMed Web of Science ®Google Scholar
• Guo JT, Sohn JA, Zhu Q, et al. Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology 2004;325:71-81
   PubMed Web of Science ®Google Scholar
• Guo JT, Zhu Q, Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol 2003;77:10769-79
   PubMed Web of Science ®Google Scholar
• Feld JJ, Ko MS, Hra K, et al. Ribavirin improved second phase kinetics througth enhanced interferon signaling in genotype 1 HCV infection. Hepatology 2008;48:389A
   Google Scholar
• Neumann AU, Rozenberg L, Reesink HW, et al. Novel mode of viral decline during telaprevir (VX-950) and PEG-IFN combination treatment predicted by a new combined intracellular and cellular hepatitis C viral dynamics model. J Hepatol 2007;46:S236
   Google Scholar
• Distefano JJ 3rd. Noncompartmental vs. compartmental analysis: some bases for choice. Am J Physiol 1982;243:R1-6
   PubMed Web of Science ®Google Scholar